BIOLINERX LTD/S (NASDAQ:BLRX) has been assigned a $3.00 price objective by investment analysts at HC Wainwright in a note issued to investors on Thursday. The firm currently has a “buy” rating on the biotechnology company’s stock.

Several other equities research analysts also recently issued reports on the company. Maxim Group set a $2.00 price target on BIOLINERX LTD/S and gave the stock a “buy” rating in a report on Thursday. Oppenheimer restated a “buy” rating on shares of BIOLINERX LTD/S in a research note on Tuesday, March 19th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. BIOLINERX LTD/S currently has an average rating of “Buy” and an average price target of $2.25.

BIOLINERX LTD/S stock traded down $0.02 during trading on Thursday, hitting $0.43. 1,794,492 shares of the company were exchanged, compared to its average volume of 1,439,063. BIOLINERX LTD/S has a 52 week low of $0.38 and a 52 week high of $1.84. The company has a market capitalization of $47.63 million, a P/E ratio of -1.59 and a beta of 1.70.

A number of large investors have recently made changes to their positions in the business. Two Sigma Securities LLC bought a new position in BIOLINERX LTD/S in the 4th quarter valued at $25,000. Menta Capital LLC bought a new position in BIOLINERX LTD/S in the 4th quarter valued at $33,000. Finally, ETF Managers Group LLC grew its stake in BIOLINERX LTD/S by 79.4% in the 4th quarter. ETF Managers Group LLC now owns 375,909 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 166,386 shares during the period. Hedge funds and other institutional investors own 33.79% of the company’s stock.

BIOLINERX LTD/S Company Profile

BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

Read More: Growth Stocks, What They Are, What They Are Not

Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with's FREE daily email newsletter.